Percutaneous Coronary Intervention

More extensive stenting improved coronary perfusion and reduced myocardial injury among high-risk patients with spontaneous coronary artery dissection, but was linked to elevated risk for procedural complications, researchers reported.

At 10 years, patients with three-vessel or left main disease who underwent PCI or CABG were more likely to survive if they were taking optimal medical therapy at 5 years, researchers reported.

Second-generation robotic system in PCI procedures.

Clopidogrel or aspirin monotherapy after 6 to 18 months of dual antiplatelet therapy following PCI.

Since the beginning of stent use, patients have received a “stent card” after PCI with information about their stent, but a study presented at the American College of Cardiology Scientific Session suggests it is not very useful.

In patients who underwent PCI with a drug-eluting stent and took dual antiplatelet therapy for 6 to 18 months, subsequent clopidogrel monotherapy was superior to aspirin monotherapy, according to data from the HOST-EXAM trial.

Biodegradable polymer sirolimus-eluting stent (Tivoli, Essen) vs. durable polymer SES (Firebird2, Microport) in patients with CAD.

DAPT for 3 months or 12 months after PCI with an everolimus-eluting stent (Synergy, Boston Scientific).

Use of a rapid high-sensitivity cardiac troponin T assay protocol for suspected ACS resulted in earlier discharge and less functional testing but was not associated with a reduction in late death or MI at 1 year.

Among patients with STEMI who underwent complete revascularization, a fractional flow reserve-guided strategy did not improve outcomes compared with an angiography-guided strategy, according to results of the FLOWER-MI trial.